Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies.
Erik MargolisGordon BrownAlan PartinBallentine CarterJames McKiernanRonald TutronePhillipp TorklerChristian FischerVasisht TadigotlaMikkel NoerholmMichael J DonovanJohan SkogPublished in: Prostate cancer and prostatic diseases (2021)
EPI is a noninvasive, easy-to-use, urine exosome-RNA assay that has been validated across 3 independent prospective multicenter clinical trials with 1212 subjects. The test can discriminate high-grade (≥GG2) from low-grade (GG1) cancer and benign disease. EPI effectively guides the biopsy-decision process independent of PSA and other standard-of-care factors.
Keyphrases
- high grade
- low grade
- prostate cancer
- radical prostatectomy
- clinical trial
- healthcare
- ultrasound guided
- papillary thyroid
- palliative care
- fine needle aspiration
- high throughput
- quality improvement
- randomized controlled trial
- cross sectional
- squamous cell
- young adults
- benign prostatic hyperplasia
- double blind
- childhood cancer
- health insurance
- phase iii